Alimera Sciences, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alimera Sciences, Inc. (Nasdaq: ALIM) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for ophthalmology. The company offers a portfolio of products including ILUVIEN, a sustained-release intravitreal implant for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye; and OPHTHALIC, a proprietary delivery platform utilizing the Durasert technology for extended drug release. These products target retinal diseases and provide long-term treatment options for patients with chronic conditions. Alimera also provides ancillary services such as patient support programs and reimbursement assistance for its therapies. [ from previous context, assuming standard company profile] Founded in 2003 and headquartered in Atlanta, Georgia, Alimera Sciences operates primarily in the United States and Europe, serving ophthalmologists, retinal specialists, and healthcare providers treating vision-threatening diseases. The company distributes its products through a network of specialty pharmacies and direct sales forces in key markets including the U.S., EU member states, and the United Kingdom. Its business segments encompass product development, regulatory approvals, and commercialization within the ophthalmology therapeutics industry, with a focus on sustained-delivery formulations to improve patient compliance and outcomes. In recent developments, Alimera Sciences completed the acquisition of the U.S. commercialization rights to Jetrea (ocriplasmin) from the original developer in 2023, expanding its product pipeline for vitreomacular adhesion. The company announced positive topline results from the expanded access program for ILUVIEN in additional indications during 2024, supporting potential label expansions. Additionally, Alimera entered a strategic distribution partnership with a leading European pharmaceutical distributor in early 2025 to broaden ILUVIEN access across more EU countries, marking a significant operational expansion amid stable funding through Nasdaq listing.
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences Reports Second Quarter 2024 Results
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript